{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=77",
    "query": {
      "condition": "Dermatologic Disorders",
      "page": 77
    },
    "page_size": 10
  },
  "pagination": {
    "page": 77,
    "page_size": 10,
    "total_count": 13622,
    "total_pages": 1363,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=78&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Dermatologic+Disorders&page=76&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T12:49:40.068Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02460289",
      "title": "Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Male Pattern of Hair Loss, Androgenic Alopecia"
      ],
      "interventions": [
        {
          "name": "Treatment: Minoxidil 5% / Botanical Hair Solution for Men",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "MALE",
        "summary": "18 Years to 60 Years · Male only"
      },
      "enrollment_count": 63,
      "start_date": "2015-05-19",
      "completion_date": "2015-11",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 1,
      "location_summary": "Richardson, Texas",
      "locations": [
        {
          "city": "Richardson",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02460289"
    },
    {
      "nct_id": "NCT05695248",
      "title": "A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hereditary Angioedema"
      ],
      "interventions": [
        {
          "name": "Navenibart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astria Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2023-02-21",
      "completion_date": "2025-03-13",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Bentonville, Arkansas + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05695248"
    },
    {
      "nct_id": "NCT06817226",
      "title": "BREAST Choice Decision Tool R21 - AIM2",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Pre-survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "BREASTChoice tool.",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Post-survey",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2024-10-10",
      "completion_date": "2026-08-28",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06817226"
    },
    {
      "nct_id": "NCT05267626",
      "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Metastatic Cancer",
        "Cutaneous Melanoma",
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AU-007",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aulos Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2022-04-04",
      "completion_date": "2027-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 10,
      "location_summary": "Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 7 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05267626"
    },
    {
      "nct_id": "NCT05704985",
      "title": "Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Colorectal Cancer",
        "Pancreas Cancer",
        "Non Small Cell Lung Cancer",
        "Head and Neck Cancer",
        "Gynecologic Cancer",
        "Skin Cancer",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "DK210 (EGFR)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "Immune checkpoint blockers",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "DEKA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2023-04-03",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2025-05-29",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Manhasset, New York • Oklahoma City, Oklahoma + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05704985"
    },
    {
      "nct_id": "NCT00415285",
      "title": "Docetaxel Followed by Capecitabine Versus Concomitant Docetaxel/Capecitabine for Early Stage Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel/Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgia Center for Oncology Research & Education",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 100,
      "start_date": "2006-12",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2007-02-13",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 3,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00415285"
    },
    {
      "nct_id": "NCT00028340",
      "title": "High-Risk Breast Duct Epithelium",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 74 Years · Female only"
      },
      "enrollment_count": 156,
      "start_date": "2003-02-20",
      "completion_date": "2022-12-16",
      "has_results": false,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00028340"
    },
    {
      "nct_id": "NCT06027268",
      "title": "Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Trilaciclib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2024-01-10",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06027268"
    },
    {
      "nct_id": "NCT03747497",
      "title": "Contezolid Acefosamil Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Skin Diseases, Bacterial",
        "Gram-Positive Bacterial Infections"
      ],
      "interventions": [
        {
          "name": "contezolid acefosamil",
          "type": "DRUG"
        },
        {
          "name": "linezolid 600 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MicuRx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 196,
      "start_date": "2018-11-15",
      "completion_date": "2019-03-26",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 7,
      "location_summary": "Chula Vista, California • La Mesa, California • Long Beach, California + 3 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Stockton",
          "state": "California"
        },
        {
          "city": "Butte",
          "state": "Montana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03747497"
    },
    {
      "nct_id": "NCT02050113",
      "title": "Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Complex Aortic Aneurysms",
        "Thoracoabdominal Aneurysms",
        "Pararenal Aneurysms",
        "Juxtarenal Aneurysms",
        "Marfan Syndrome",
        "Ehlers-Danlos Syndrome",
        "Loeys-Dietz Syndrome",
        "Aortic Arch Aneurysm"
      ],
      "interventions": [
        {
          "name": "Custom Made Fenestrated or Branched Stent Graft",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Andres Schanzer",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2014-03",
      "completion_date": "2030-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-11-05T12:49:40.068Z",
      "location_count": 1,
      "location_summary": "Worcester, Massachusetts",
      "locations": [
        {
          "city": "Worcester",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02050113"
    }
  ]
}